compared to 16.5% in the placebo cohort. Novartis 'took data to heart' before slimming clinical pipeline by 40%, says CEO BioCity has since launched a phase 3 trial of SC0062 in Chinese patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback